GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Personalis Inc (NAS:PSNL) » Definitions » Equity-to-Asset

Personalis (Personalis) Equity-to-Asset : 0.62 (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Personalis Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Personalis's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $120.69 Mil. Personalis's Total Assets for the quarter that ended in Mar. 2024 was $195.28 Mil. Therefore, Personalis's Equity to Asset Ratio for the quarter that ended in Mar. 2024 was 0.62.

The historical rank and industry rank for Personalis's Equity-to-Asset or its related term are showing as below:

PSNL' s Equity-to-Asset Range Over the Past 10 Years
Min: -2.76   Med: 0.71   Max: 0.88
Current: 0.62

During the past 7 years, the highest Equity to Asset Ratio of Personalis was 0.88. The lowest was -2.76. And the median was 0.71.

PSNL's Equity-to-Asset is ranked better than
53.62% of 235 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.59 vs PSNL: 0.62

Personalis Equity-to-Asset Historical Data

The historical data trend for Personalis's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Personalis Equity-to-Asset Chart

Personalis Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial 0.68 0.80 0.78 0.75 0.58

Personalis Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.71 0.71 0.67 0.58 0.62

Competitive Comparison of Personalis's Equity-to-Asset

For the Diagnostics & Research subindustry, Personalis's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Personalis's Equity-to-Asset Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Personalis's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Personalis's Equity-to-Asset falls into.



Personalis Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Personalis's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=129.441/225.099
=0.58

Personalis's Equity to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

Equity to Asset (Q: Mar. 2024 )=Total Stockholders Equity/Total Assets
=120.694/195.276
=0.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Personalis  (NAS:PSNL) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Personalis Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Personalis's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Personalis (Personalis) Business Description

Traded in Other Exchanges
Address
6600 Dumbarton Circle, Fremont, CA, USA, 94555
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Liquid Biopsy, NeXT Dx Test, and other Pharma Research Solutions.
Executives
Richard Chen officer: Chief Scientific Officer C/O PERSONALIS, INC., 1330 O'BRIEN DRIVE, MENLO PARK CA 94025
Stephen Michael Moore officer: General Counsel C/O PERSONALIS, INC., 1330 O'BRIEN DRIVE, MENLO PARK CA 94025
Aaron Tachibana officer: Chief Financial Officer 400 NORTH MCCARTHY BLVD, MILPITAS CA 95035
Christopher M Hall officer: President 6600 DUMBARTON CIRCLE, FREMONT CA 94555
Kenneth J Widder director 10070 BARNES CANYON ROAD, SAN DIEGO CA 92121
Lonnie Shoff director C/O PERSONALIS, INC., 1330 O'BRIEN DRIVE, MENLO PARK CA 94025
John Stephen West director, officer: President and CEO C/O PERSONALIS, INC., 6600 DUMBARTON CIRCLE, FREMONT CA 94555
Lightspeed Venture Partners Select Iv, L.p. other: Affiliate of 10% Owner 2200 SAND HILL ROAD, MENLO PARK CA 94025
Olivia Kyusuk Bloom director C/O GERON CORP, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Myers Woodrow A Jr director 1 N ILLINOIS SREET 2101, INDIANAPOLIS IN 46204
Llp Abingworth 10 percent owner 38 JERMYN STREET, LONDON X0 SW1Y 6DN
Ken Ludlum director
Arif Janmohamed other: Affiliate of 10% Owner 2200 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025
Lightspeed Ultimate General Partner Select Iv, L.l.c. other: Affiliate of 10% Owner 2200 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025
Lightspeed General Partner Select Iv, L.p. other: Affiliate of 10% Owner 2200 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025